
    
      This is a randomized, double-blind, and placebo-controlled study. Subjects with evaluation
      and confirmation that inclusion and exclusion criteria are met, will be treated with
      naltrexone sustained release 15mg once per day and bupropion sustained release 150mg once per
      day in the first two weeks, and naltrexone 25mg once per day and bupropion 300mg once per day
      during the rest of the study.The purpose of this research is to observe the efficacy of
      Naltrexone and Bupropion on weight loss and smoking cessation compared to placebo.
    
  